Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial-mesenchymal transition and invasion in prostate cancer.

Amatangelo MD, Goodyear S, Varma D, Stearns ME.

Carcinogenesis. 2012 Oct;33(10):1965-75. doi: 10.1093/carcin/bgs227. Epub 2012 Jul 12.

2.

Retraction: Role of ribosomal protein RPS2 in controlling let-7a expression in human prostate cancer.

Wang M, Hu Y, Amantagelo MD, Stearns ME.

Mol Cancer Res. 2012 Apr;10(4):570. doi: 10.1158/1541-7786.MCR-12-0085. Epub 2012 Mar 20. No abstract available.

4.

Role of ribosomal protein RPS2 in controlling let-7a expression in human prostate cancer.

Wang M, Hu Y, Amatangelo MD, Stearns ME.

Mol Cancer Res. 2011 Jan;9(1):36-50. doi: 10.1158/1541-7786.MCR-10-0158. Epub 2010 Dec 8. Retraction in: Wang M, Hu Y, Amantagelo MD, Stearns ME. Mol Cancer Res. 2012 Apr;10(4):570.

5.

Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice.

Stearns ME, Amatangelo MD, Varma D, Sell C, Goodyear SM.

Am J Pathol. 2010 Dec;177(6):3169-79. doi: 10.2353/ajpath.2010.100330. Epub 2010 Oct 22.

6.

Role of the VEGFR3/VEGFD receptor axis in TGFbeta1 activation of primary prostate cell lines.

Goodyear SM, Kheyfets SB, Garcia FU, Stearns ME.

Prostate. 2009 Jun 15;69(9):982-90. doi: 10.1002/pros.20945.

PMID:
19301310
7.

Dysplasia of human prostate CD133(hi) sub-population in NOD-SCIDS is blocked by c-myc anti-sense.

Goodyear SM, Amatangelo MD, Stearns ME.

Prostate. 2009 May 15;69(7):689-98. doi: 10.1002/pros.20918.

8.

RPS2: a novel therapeutic target in prostate cancer.

Wang M, Hu Y, Stearns ME.

J Exp Clin Cancer Res. 2009 Jan 12;28:6. doi: 10.1186/1756-9966-28-6.

9.

The ABCA5 protein: a urine diagnostic marker for prostatic intraepithelial neoplasia.

Hu Y, Wang M, Veverka K, Garcia FU, Stearns ME.

Clin Cancer Res. 2007 Feb 1;13(3):929-38.

10.

Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor.

Dolloff NG, Shulby SS, Nelson AV, Stearns ME, Johannes GJ, Thomas JD, Meucci O, Fatatis A.

Oncogene. 2005 Oct 13;24(45):6848-54.

12.
14.

Evidence for prostate cancer-associated diagnostic marker-1: immunohistochemistry and in situ hybridization studies.

Ohkia A, Hu Y, Wang M, Garcia FU, Stearns ME.

Clin Cancer Res. 2004 Apr 1;10(7):2452-8.

15.
17.
18.
19.

IL-10/IL-10 receptor signaling regulates TIMP-1 expression in primary human prostate tumor lines.

Wang M, Hu Y, Shima I, Stearns ME.

Cancer Biol Ther. 2002 Sep-Oct;1(5):556-63.

PMID:
12496489
20.

Significance of cysteine rich transcription factor (CRTF) in the synthesis of tissue inhibitor of metalloproteinases 1 (TIMP-1) in gastrointestinal cancers.

Kanazawa M, Ogata Y, Aoyagi K, Stearns ME, Shirouzu K.

J Exp Clin Cancer Res. 2001 Mar;20(1):145-51.

PMID:
11370821
21.

Selective estrogen receptor modulators. An aid in unraveling the links between estrogen and breast cancer.

Fuqua SA, Russo J, Shackney SE, Stearns ME.

Postgrad Med. 2001 Mar;Spec No:3-10. Review.

PMID:
11296736
22.
23.

Increased cellularity of tumor-encased native vessels in prostate carcinoma is a marker for tumor progression.

Garcia FU, Taylor CA, Hou JS, Rukstalis DB, Stearns ME.

Mod Pathol. 2000 Jul;13(7):717-22.

24.
25.
28.
30.

Specific transcription factors prognostic for prostate cancer progression.

Aoyagi K, Shima I, Wang M, Hu Y, Garcia FU, Stearns ME.

Clin Cancer Res. 1998 Sep;4(9):2153-60.

31.

Workgroup 2: human xenograft models of prostate cancer.

Stearns ME, Ware JL, Agus DB, Chang CJ, Fidler IJ, Fife RS, Goode R, Holmes E, Kinch MS, Peehl DM, Pretlow TG 2nd, Thalmann GN.

Prostate. 1998 Jun 15;36(1):56-8. No abstract available.

PMID:
9650917
32.
33.

In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer.

Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME.

Clin Exp Metastasis. 1997 May;15(3):246-58.

PMID:
9174126
34.
35.
36.
37.

Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice.

Stearns ME, Wang M.

Invasion Metastasis. 1996;16(3):116-31.

PMID:
9186547
41.

Keratinocyte growth factor and receptor mRNA expression in benign and malignant human prostate.

McGarvey TW, Stearns ME.

Exp Mol Pathol. 1995 Aug;63(1):52-62.

PMID:
8759054
42.

Taxol reduces circulating tumor cells to prevent bone metastases in SCID mice.

Stearns ME.

Invasion Metastasis. 1995;15(5-6):232-41.

PMID:
8765198
43.
44.
49.

Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity.

Stearns ME, Wang M, Fudge K.

Cancer Res. 1993 Jul 1;53(13):3073-7. Erratum in: Cancer Res 1993 Dec 1;53(23):5831.

50.

Autocrine factors, type IV collagenase secretion and prostatic cancer cell invasion.

Stearns ME, Stearns M.

Cancer Metastasis Rev. 1993 Mar;12(1):39-52. Review.

PMID:
8448826

Supplemental Content

Loading ...
Support Center